According to the RNC Pharma® “Production of Medicinal Products in Russia” database, from January through October 2025, pharmaceutical companies localized in the Russian Federation released into circulation more than 3.26 billion packs of finished medicinal products (FMPs), equivalent to 68.89 billion minimum dosage units (MDUs). Over the year, the physical volume of medicinal product manufacturing declined by 4% in packs, while the output in MDUs remained virtually unchanged (+0.8%). For the first ten months of the current year, the total volume of FMP production in the country reached 809.7 billion rubles (at manufacturer shipment prices, including VAT). The year-over-year growth compared with January–October 2024 amounted to 17% in Russian currency.

In the fourth quarter, production activity among pharmaceutical manufacturers typically increases; however, in October 2025, physical output indicators rose only marginally compared with September (+2% in packs), and remained almost unchanged versus October of the previous year (+0.2%). In total, companies localized in Russia released approximately 368.6 million packs of finished medicinal products into circulation, equivalent to 7.8 billion MDUs. At the same time, the monetary volume of FMP shipments in October 2025 reached 93.6 billion rubles, which is 28.9% higher than a year earlier.

Among the top ten key pharmaceutical manufacturers, only four companies demonstrated an increase in physical output. The leading company, Ozon Pharmaceuticals, increased its shipment volume by 24.7% in packs relative to January–October 2024. Within the Top-50 corporations (ranked by physical production volume), fewer than half reported positive annual dynamics. The highest growth was recorded at NII Medicine and Standardization (NIIMIS): its product output increased 8.5-fold, with the portfolio represented by various alcohol-based medicinal products.

Second place in the ranking was taken by Zhenel, which increased production by 50.3% in packs, driven primarily by antiseptics such as iodine, brilliant green, and other traditional products. AstraZeneca ranked third with annual growth of +42%; the company demonstrated substantial increases in output for brands such as Forxiga (+73%) and Nexium (up 14.5-fold). Some of the fastest-growing manufacturers have portfolios comprising fewer than ten trade names, while others manage hundreds—the broadest assortment was recorded at Ozon Pharmaceuticals, with approximately 300 brands. Over the year, the company’s production volume increased by 25%, with nearly 301.7 million packs shipped from January through October 2025.

Among the highlighted companies, notable results were also recorded for Pranafarm (+36%), driven mainly by increased production of angiotensin II antagonists, particularly losartan, and Menarini (+30%), where performance was largely supported by the product MIG, whose output grew 18-fold.

Table. Top 10 corporations by growth in physical output of finished medicinal products in Russia (including production of foreign pharmaceutical companies at their own and contract sites) among the Top-50 companies, January–October 2025